All In Biotech

Drug Trial Radar · NCT06905873

A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Non-segmental Vitiligo

A Randomized, Double-Blind, Placebo Controlled, Multi-center Study to Evaluate the Safety and Efficacy of FB102 in Patients With Non-Segmental Vitiligo

Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

64

Planned (sponsor's estimate)

Start

Mar 25, 2025

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Forte Biosciences, Inc.Industry
Sponsor type
Industry
First posted
Apr 2, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Randomized, Double-Blind, Placebo Controlled, Multi-center Study to Evaluate the Safety and Efficacy of FB102 in Patients with Non-Segmental Vitiligo.

Conditions

  • Vitiligo

Interventions

  • FB102Drug

    Route of administration- Intravenous (IV)

  • PlaceboDrug

    Route of administration- Intravenous (IV)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment-emergent adverse events (TEAEs) and Serious Adverse events (SAE) following treatment with FB102Time frame: Upto 16 Weeks post first dose administration
  2. Percent change from Baseline in central read facial-vitiligo area scoring index (F-VASI)Time frame: Upto 16 Weeks post first dose administration
  3. Number of participants with percent change from Baseline in central read facial-vitiligo area scoring index (F-VASI)Time frame: Upto 16 Weeks post first dose administration

Locations

6 sites in 2 countries. Site status is shown where the registry gives one.

  • Skin & Cancer Foundation Australia - The Skin Hospital

    Darlinghurst, New South Wales, Australia

  • Novatrials

    Kotara, New South Wales, Australia

  • Cornerstone Dermatology

    Coorparoo, Queensland, Australia

  • Optimal Clinical Trials North

    Auckland, Auckland, New Zealand

  • Optimal Clinical Trials Central

    Auckland, Auckland, New Zealand

  • Momentum Pukehoke

    Auckland, Auckland, New Zealand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.